Clinical trials: Metabolic Disease
Obesity, Dyslipidemia
Dose-Ranging Study Evaluating AVE1625 in Abdominally Obese Patients With Atherogenic Dyslipidemia
Primary objective: to assess the effect of AVE1625 on weight loss over a period of 24 weeks in abdominally obese patients with atherogenic dyslipidemia.
- Trial name
- NCT00345410
- Testing
- AVE1625 B
- Where
- United States
- Volunteers
- 345 people
- Sponsor
- Sanofi
Hypercholesterolemia
Lipid-lowering Effect of Plant Stanol Drink
To determine the effect of investigational products on serum LDL cholesterol.
- Trial name
- NCT01716390
- Testing
- Drink that contains plant stanols
- Where
- Sweden
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Raisio Group
Obesity
Effects of HMOs on the Faecal Microbiota and on Host Metabolism in Obese Children
The study is a randomised, placebo-controlled, double-blind, parallel study in obese children. A total of 75 obese children in the age 5 to 10 years, enrolled in a childhood obesity treatment program, will be included.
- Trial name
- NCT02786160
- Testing
- HMO, Dextropur
- Where
- Denmark
- Volunteers
- 75 people
- Sponsor
- Glycom A/S
Type 2 Diabetes
Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Ultra Low Doses of Dapagliflozin in Healthy Subjects
The purpose of this study is to evaluate the pharmacodynamics (PD), pharmacokinetics (PK), safety and tolerability following single oral doses of 0.001 mg to 2.5 mg dapagliflozin in healthy subjects.
- Trial name
- ULDS (NCT01135446)
- Testing
- dapagliflozin
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Type 2 Diabetes (T2DM)
Evaluate the Efficacy and Safety of GZR33 Injection in Patients With Type 2 Diabetes
Evaluate the efficacy of GZR33 Injection and Insulin Degludec Injection (Tresiba®) in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Oral Antidiabetic Drugs.
- Trial name
- NCT07527078
- Testing
- GZR33 Injection, Insulin Degludec Injection (Tresiba®)
- Where
- China
- Volunteers
- 350 people
- Sponsor
- Gan & Lee Pharmaceuticals.
Anemia, Iron Deficiencies
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CTX001 in Healthy Adults.
This study is testing CTX001 for certain conditions where the body does not have enough available iron or has difficulty storing or moving iron properly.
- Conditions
- Anemia, Iron Deficiencies, Chronic Kidney Disease
- Trial name
- NCT07577817
- Testing
- CTX001 With and Without Iron, CTX001 With Iron, CTX001 Multiple Dose
- Where
- Australia
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Cajal Therapeutics Inc.
Diabetes, Diabetes Mellitus, Type 2
A Trial to Assess the Pharmacokinetics, Safety and Tolerability of Semaglutide in Healthy Chinese Subjects
The main purpose of the trial is to assess the pharmacokinetics of semaglutide (i.e. the way the drug is distributed in the body over a period of time) following once-weekly administration of semaglutide in healthy Chinese…
- Trial name
- NCT03288740
- Testing
- Semaglutide 0.5 mg, Semaglutide 1.0 mg
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Homozygous Familial Hypercholesterolemia (HoFH)
A Long-term Follow-up Study to Evaluate the Safety and Efficacy of RGX-501
This long-term observational study is designed to follow subjects who, during another Clinical Study, received gene therapy treatment used to treat their Homozygous Familial Hypercholesterolemia (HoFH) disease.
- Trial name
- NCT04080050
- Testing
- Single intravenous (IV) dose of human Low Density Lipoprotein Receptor (LDLR) Gene Therapy
- Where
- 6 sites in United States, Canada and 1 more
- Volunteers
- 8 people
- Sponsor
- REGENXBIO Inc.
Barth Syndrome
A Trial to Evaluate Safety, Tolerability and Efficacy of Elamipretide in Subjects With Barth Syndrome
A randomized, double-blind cross over trial to evaluate the safety, efficacy, and tolerability of elamipretide in subjects with Barth syndrome.
- Trial name
- TAZPOWER (NCT03098797)
- Testing
- Elamipretide
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Stealth BioTherapeutics Inc.
Diabetes Mellitus, Foot Ulcer
Becaplermin Use and Cancer Risk in a Patient Population of U.S. Veterans With Diabetes
The purpose of this study is to evaluate risk of cancer incidence and mortality associated with the use of REGRANEX (becaplermin) in patients with diabetes who are members of a U.S. Veterans Health Administration.
- Conditions
- Diabetes Mellitus, Foot Ulcer, Diabetic Foot, Diabetic Neuropathies
- Trial name
- NCT01235260
- Testing
- Becaplermin nonusers, Becaplermin users
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Diabetes Mellitus
A Clinical Study Comparing the Relative Bioavailability and Safety of SHR-3167 Injection
This study is a randomized, parallel, open-label Phase I clinical trial aimed at comparing the bioavailability and safety of different specifications of SHR-3167 injection, with healthy subjects as the research subjects.
- Trial name
- NCT07489482
- Testing
- SHR-3167 Injection
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Diabetes, Diabetes Mellitus, Type 1
Safety and Efficacy of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart as Mealtime Insulin in Type 1 Diabetes
This trial is conducted in Europe and the United States of America (USA). The purpose of this study is to test whether insulin detemir is a safe and at least as effective alternative to insulin glargine for the control of blood…
- Trial name
- NCT00095082
- Testing
- insulin detemir, insulin glargine, insulin aspart
- Where
- 81 sites in United States, Finland and 5 more
- Volunteers
- 447 people
- Sponsor
- Novo Nordisk A/S
Obesity, Heart Failure With Preserved Ejection Fraction (HFpEF)
A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial
The main purpose of this study is to assess the efficacy and safety of Tirzepatide (LY3298176) in participants with heart failure with preserved ejection fraction and obesity.
- Trial name
- NCT04847557
- Testing
- Tirzepatide
- Where
- 146 sites in United States, Argentina and 8 more
- Volunteers
- 731 people
- Sponsor
- Eli Lilly and Company
Obesity
Effect of a Novel Nutraceutical on Weight Loss and Weight Maintenance in Obese Subjects
The purpose of this 2-stage intervention study is to investigate the effect of a novel nutraceutical (containing tetrahydro iso-alpha acids derived from hops) on weight loss and weight loss maintenance in obese participants.
- Trial name
- NCT01656681
- Testing
- THIAA
- Where
- United States
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- MetaProteomics LLC
Transthyretin (TTR) Amyloid Cardiomyopathy
Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy
Open label study to evaluate tafamidis for the treatment of transthyretin cardiomyopathy
- Trial name
- NCT02791230
- Testing
- Tafamidis
- Where
- 80 sites in United States, Argentina and 15 more
- Volunteers
- 1,733 people
- Sponsor
- Pfizer
Small Cell Lung Cancer
Mass Balance Study of [14C]Chiauranib
Chiauranib , which simultaneously targets against VEGFR/Aurora B/CSF-1R, several key kinases involved in tumor angiogenesis, tumor cell mitosis, and chronic inflammatory microenvironment.
- Trial name
- NCT05371899
- Testing
- Chiauranib
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Chipscreen Biosciences, Ltd.
Gout, Chronic Kidney Disease (CKD)
A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment
This study evaluates the safety and efficacy of lesinurad administered with an XOI versus a placebo plus an XOI in gout participants who have moderate renal impairment and who are not at target level of serum urate (sUA).
- Trial name
- NCT03226899
- Testing
- Lesinurad, XOI, colchicine
- Where
- 116 sites in United States, Czechia and 2 more
- Volunteers
- 242 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.
Type 2 Diabetes Mellitus
A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes Mellitus
The purpose of this trial is to examine the efficacy and safety of once-weekly LY2189265 (dulaglutide) in participants with type 2 diabetes mellitus taking an oral antihyperglycemic medication (OAM).
- Trial name
- NCT01584232
- Testing
- LY2189265, Insulin glargine, Sulfonylureas (SU)
- Where
- 15 sites in Japan
- Volunteers
- 361 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Clinical Characteristics and Practice Patterns of Type 2 Diabetes Mellitus Patients Treated With OADs in Japan: Analysis of Medical and Health Care Database of the MDV
Appropriate use of oral antidiabetic drugs (OADs) including dose-reduction is important for patient's safety in T2DM patients with renal impairment (RI).
- Trial name
- NCT03092752
- Testing
- oral antidiabetic drugs
- Where
- Japan
- Volunteers
- 162,116 people
- Sponsor
- Boehringer Ingelheim
Diabetes
Evaluation of an Ascensia Lancing System
The purpose of this study was to determine if untrained subjects with diabetes could perform basic tasks with the Styx lancing device to obtain adequate blood volume from fingerstick and palm lancings for Blood Glucose Meter…
- Trial name
- NCT02606838
- Testing
- Styx Lancing Device
- Where
- United States
- Volunteers
- 119 people
- Sponsor
- Ascensia Diabetes Care
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.